Loading...
•
Jun 30, 2022
Checkpoint Therapeutics Q2 2022 Earnings Report
Reported financial results for the second quarter ended June 30, 2022.
Key Takeaways
Checkpoint Therapeutics announced positive interim results from the registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma and successful completion of pre-BLA meetings.
Announced positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma in June 2022.
Successfully completed pre-BLA meetings in July 2022.
Biologics license application submission for both metastatic and locally advanced cutaneous squamous cell carcinoma on track for later this year.
Continued to advance commercial planning to enable a successful launch upon possible approval next year.
Forward Guidance
The company is on target to submit the cosibelimab BLA in late 2022 and believes their price disruptive strategy could generate substantial market share for cosibelimab in the U.S.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...